Use of exendin and analogs thereof to delay or prevent cardiac remodeling
US8946149B2 · kind B2 · utility
4Cited by
18References
24Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 11, 2006 |
| Grant date | Feb 3, 2015 |
| Priority date | — |
| Expiry date | Jul 22, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates generally to the novel use of cardioprotective incretin compounds (CICs) such as GLP-1 and exendin and agonists thereof, including analogs and derivatives to prevent, delay, attenuate, or ameliorate cardiac remodeling. The present invention relates to methods for using CICs for the treatment of conditions associated with cardiac remodeling. The present invention further relates to methods for using CICs for the reduction of the risk or severity of congestive heart failure.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.